Biologics manufacturing facility to open in Rockville

Samsung Biologics, a biotechnology company based in South Korea, announced plans to open its first U.S. manufacturing facility in Rockville, according to Gov. Wes Moore‘s office. 

Last month, Samsung Biologics announced it acquired GSK’s Rockville manufacturing facility for $280 million and now plans to expand the site’s current drug substance capacity, upgrading the technology to support what Moore’s office called a “growing demand for critical biologic medicines.” 

Through the acquisition, Samsung plans to retain more than existing 500 jobs at the site and create additional jobs, according to state officials. 

The new Montgomery County facility will include expanded drug substance manufacturing capacity and will accommodate clinical and commercial production, according to a the governor’s office.

“We are thrilled that Samsung Biologics has selected Maryland for their first U.S. manufacturing facility, a testament to our state’s leadership in life sciences, our highly-skilled workforce and the commitment of our private and public sector to advance patient health around the globe,” Moore said. 

“During our Asia trade mission, we were excited to share with Samsung Biologics executives the many reasons why Maryland is an ideal foothold from which the company can execute its long-term strategy to expand in the U.S. market.”

Last spring, Moore joined Maryland Department of Commerce Secretary Harry Coker for a meeting with Samsung Biologics executives during an international trade and investment mission to Japan and South Korea intended to promote economic growth and workforce development.

“The acquisition of GSK’s Rockville manufacturing campus by Samsung Biologics represents a significant achievement for Montgomery County,” Montgomery County Executive Marc Elrich said.

“We proudly welcome Samsung Biologics to Montgomery County, Maryland, and anticipate their contribution in enhancing our economy, workforce, and status as a global life sciences hub.”

The news follows a development from November 2025 in which Moore and AstraZeneca announced a $2 billion investment to expand manufacturing in Frederick and build a new clinical facility in Gaithersburg.